NeuroPace (NPCE) Liabilities and Shareholders Equity (2020 - 2026)
NeuroPace (NPCE) posted quarterly Liabilities and Shareholders Equity of $98.9 million for Q1 2026, down 10.26% year-over-year from $110.2 million in Q1 2025, and down 6.32% quarter-over-quarter from $105.6 million in Q4 2025.
NeuroPace (NPCE) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
NeuroPace's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $98.9 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 10.26% year-over-year to $98.9 million; the TTM figure through Mar 2026 stood at $417.8 million (up 5.63% YoY), while the FY2025 annual figure was $105.6 million, up 11.54% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $98.9 million, down from $105.6 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $129.0 million in Q1 2022, with the low at $94.4 million in Q2 2024.
- The 5-year median for Liabilities and Shareholders Equity is $106.1 million (2025), against an average of $106.5 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 156.3% in 2022, while the deepest fall reached 19.34% in 2022.
- NeuroPace's Liabilities and Shareholders Equity stood at $114.1 million in 2022, then decreased by 5.66% to $107.7 million in 2023, then declined by 12.08% to $94.6 million in 2024, then grew by 11.54% to $105.6 million in 2025, then dropped by 6.32% to $98.9 million in 2026.
- Business Quant data shows NPCE's Liabilities and Shareholders Equity at $98.9 million in Q1 2026, $105.6 million in Q4 2025, and $107.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 10.74 Bn |
| 10 | NeuroPace | 479.51 Mn | 427.81 Mn | 18.91 Mn | 96.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.99 Mn |
| Mar 31, 2026 | 98.90 Mn |
| Dec 31, 2025 | 105.57 Mn |
| Sep 30, 2025 | 107.26 Mn |
| Jun 30, 2025 | 106.11 Mn |
| Mar 31, 2025 | 110.21 Mn |
| Dec 31, 2024 | 94.65 Mn |
| Sep 30, 2024 | 96.30 Mn |
| Jun 30, 2024 | 94.39 Mn |
| Mar 31, 2024 | 98.85 Mn |
| Dec 31, 2023 | 107.65 Mn |
| Sep 30, 2023 | 99.30 Mn |
| Jun 30, 2023 | 102.23 Mn |
| Mar 31, 2023 | 106.27 Mn |
| Dec 31, 2022 | 114.11 Mn |
| Sep 30, 2022 | 120.47 Mn |
| Jun 30, 2022 | 118.54 Mn |
| Mar 31, 2022 | 128.98 Mn |
| Dec 31, 2021 | 133.56 Mn |
| Sep 30, 2021 | 141.26 Mn |